Objective: To analyze the potential for different aspects of anxiety to modify the effect of impaired functioning in major depressive disorder (MDD).
Abbreviations

Clinical Implications
• Impaired functioning is associated with depression. Few studies have analyzed the impact of comorbidity in relation to daily functioning.
• Poorer functioning was correlated with high trait anxiety scores but not with high state anxiety scores.
Limitations
• The use of a cross-sectional design has implications for generalizability and for establishing causal relations.
• The study includes the use of patient self-reports.
A prevalent and disabling disorder, MDD has been identified as a major determinant of the burden of disease. 1, 2 WHO reports determine that MDD is currently the fourth leading medical condition contributing to global burden of disease, and is estimated to rise to second by the year 2030. 3 Further, MDD is the leading cause of years of life lived with disability. 4 MDD is associated with decreased physical, social, and work functioning. Previous studies have demonstrated that patients with MDD were more likely to report limitations in self-support care, more disability days, more productivity loss-related costs, poorer physical and emotional health, and an increased use of health services. [5] [6] [7] [8] [9] [10] Although the association between MDD and disability has been well established, [11] [12] [13] [14] [15] [16] [17] [18] their reciprocal nature and the confounder factors that take part in the process makes the understanding of the association very complex. Several factors that influence the link between MDD and disability have been previously identified but studies have not been able to determine the contribution of these factors to the impairment. 15, [19] [20] [21] [22] Among variables associated with impaired functioning in MDD, psychiatric comorbidity is a clinical variable that has been shown to be a risk factor for disability. 13, 21, 23, 24 Anxiety disorder is the most comorbid condition associated with MDD. 25 Data from general and clinical populations suggest that the comorbidity of depressive and anxiety disorders commonly exceed 50%. [25] [26] [27] [28] [29] Comorbidity of anxiety and depressive disorders has been related to greater severity and poorer treatment response. [30] [31] [32] Also anxiety disorder seems to have additive effects on increased disability, poorer recovery from medical illness, higher odds for long-term absenteeism, impaired work performance, and high annual lost productivity cost. 10, 30, 33 Despite a recent focus on functioning measurement in patients with MDD, 34 few studies have analyzed the impact of comorbidity in relation to daily functioning. Most studies have examined functioning in MDD overlooking comorbid diagnoses and for that reason results are of limited interpretation. 35 Moreover, the available literature does not offer a clear explanation about the degree to which these functioning impairments are due to different aspects of anxiety, that is, not only the presence of anxiety but also the severity of anxiety and depression or anxiety as a trait.
Our focus is on the impact of anxiety disorder on everyday functioning of patients with MDD. Our study aimed to investigate the potential for different aspects of anxiety (current comorbid anxiety disorders, anxiety severity, anxiety, trait anxiety, and state anxiety) to increase the effect of impaired functioning in a large sample of patients with MDD using a specific comprehensive WHO instrument, the WHO-DAS-II. 36 
Methods
Design, Sample, and Setting
A Spanish national cross-sectional epidemiologic study was designed. A total of 300 psychiatrists-distributed proportionally by provinces and health centres in 17 of Spain's regional communities-were randomly selected to participate in our study. Rural, urban, and age proportions were also included. A total of 245 psychiatrists joined the study after having received an open invitation (84.6% was l'anxiété a un effet modéré sur la déficience fonctionnelle chez les patients du TDM.
Conclusions :
Nos résultats suggèrent que le TDM et la gravité de l'anxiété semblent être associés significativement avec le fonctionnement déficient chez les patients souffrant du TDM, mais qu'ils n'expliquent qu'une proportion modérée de la variance. the response rate). Each psychiatrist was asked to recruit 5 consecutive eligible patients. In case of refusal or exclusion, the next patient fulfilling inclusion criteria attending the setting was enrolled until each psychiatrist obtained a total of 5 patients. Finally, 1226 psychiatric outpatients were included. The psychiatrists were instructed in the use of the instruments, which were presented in an easy-to-use computerized format specifically designed for the study. The recruitment period was 12 weeks (April 1, 2011 to June 30, 2011) . Inclusion criteria for our study were as follows: patients had to be 18 years or older; have a current MDE using DSM-IV 37 diagnostic criteria; and give written informed consent. Exclusion criteria were as follows: failure to meet any of the above criteria; inability to complete the protocol due to a medical condition; and a comorbid psychiatric disorder (psychosis or dementia). The study protocol was approved by the local ethics committee. The full name is Comité ético de investigación clínica-Islas Baleares [Ethics Committee for Clinical Research-Balearic Islands].
Measures
Sociodemographic and clinical characteristics of patients with MDD were collected using a CRF. The patients were instructed in the use of the CRFs, which were presented in an easy-to-use computerized format specifically designed for the study. The CRFs included sex; marital status; rural or urban area; living alone or accompanied; educational level; work status; BMI; use of alcohol, caffeine, and tobacco; and physical activity. For all patients, the following clinical depressive variables were assessed: age of onset, MDE (single episode or recurrent episodes), pharmacological and nonpharmacological treatment, and the CGI.
The WHO-DAS-II
The 12-item version of the WHO-DAS-II was used to assess functional limitation. 38, 39 In each item, subjects have to estimate the magnitude of the disability during the previous 30 days (from none = 1, to extreme or cannot do = 5). The total score may vary from 0 to 100, with higher scores reflecting greater disability.
The HARS
The HARS 40,41 is a 14-item interviewer scale that assesses the subject's level of anxiety. Items are scored from 0 (not present) to 3 (severe). The total score ranges from 0 to 56 points.
The STAI-S and STAI-T
The STAI-S 42 assesses the state of anxiety in 20 items of intensity (from 0 = none, to 3 = much at time of evaluation). STAI-T assesses the trait of anxiety in 20 items of frequency (from 0 = almost never, to 3 = almost always generally, in most cases). 43 The QIDS To assess the severity of depressive symptoms, we used the QIDS 44 16-item, Self-Report, Spanish version. 45 This instrument covers only the 9 diagnostic symptom domains used to characterize an MDE, without items to assess atypical, melancholic, or their commonly associated symptoms and is administered by the patient self-report.
Depression and anxiety comorbidity was defined using double criteria: patients with MDD or MDE had to have a DSM-IV diagnosis of anxiety disorder made by a psychiatrist and a HARS cut-off point of 15 or more.
Statistical Analysis
Descriptive analysis was computed in terms of mean, standard deviation, and ranges for continuous variables, and frequency with percentage for ordinal and nominal variables. Discrete variables were compared using the chisquare test. Continuous variables were normally distributed (Shapiro-Wilk P > 0.05) and therefore 2 independent sample Student t tests were used for variable comparisons. Correlation analysis between the variables was performed using Pearson product-moment correlation coefficient. Multiple linear regression analysis using the enter method approach was used to evaluate the relative strength of the effects of age, comorbid anxiety disorder, HARS, QIDS, STAI-T, STAI-S scores, and BMI on functional limitation. For all statistical analyses, a P value of less than 0.05 was considered to be statistically significant. Analyses were performed using the statistical software program IBM SPSS Statistics 19.0 (IBM SPSS Inc, Armonk, NY).
Results
Sample Description
Final analyses were undertaken on 1226 subjects, with 43.1% of patients having a comorbid depression and anxiety disorder and 56.9% having a pure MDD.
Sociodemographic characteristics of the sample and comparisons between both groups (comorbid and noncomorbid) are shown in Table 1 . The sample was predominantly female (62.8%) and the mean age was 47.76 years (SD 13.8). Most were married (58.3%) and lived accompanied (79.9%) in an urban area (73.4%). Patients with MDD and patients with MDD and anxiety disorder did not differ significantly across sociodemographic variables except for education level (χ 2 = 8.16, df = 1225, P = 0.005) Lifestyle variables and psychopathological variables are shown in Table 1 . Statistically significant differences between groups were found in drinking alcohol (23.5%, compared with 18.6%; P = 0.04) and physical activity (mean 2.68, SD 1.1, compared with mean 2.84, SD 1.2; P = 0.02). Differences were also found in the number of recurrent MDEs (mean 2.95, SD 1.87, compared with mean 2.50, SD 1.66; P = 0.01) and psychopharmacological treatment: anxiolytics (86.0% of the comorbid patients, compared with 49.7 of noncomorbid patients; P < 0.001), hypnotics (32.2, compared with 24.4; P = 0.002), and antipsychotics (8.1%, compared with 6.2%; P = 0.03). Also, nonpharmacological treatment was significantly more frequent in the comorbid group (44.4%, compared with 32.7%, P < 0.001). Patients with MDD had higher scores in the CGI than patients with depressive and anxiety disorders (mean 5.69, SD 1.01, compared with mean 5.18, SD 0.9; P < 0.001). Finally, 
Correlation Analysis Results
Pearson correlations were used to examine bivariate relations between analyzed variables ( Table 2 ). Poorer functioning correlated significantly with age (Pearson r = 0.16, P = 0.001), severity of MDE (r = 0.778, P = 0.001), severity of anxiety disorder (r = 0.649, P = 0.001), higher number of recurrent MDEs (r = 0.081, P = 0.01), STAI-T scores (r = 0.402, P = 0.001), and higher BMI (r = 0.123, P = 0.001) but not with age of onset of MDD (r = 0.04, P = 0.41) or with STAI-S scores (r = 0.032, P = 0.26).
Multiple Regression Analysis Results
To analyze the effect of studied independent variables on functioning, multiple linear regression analysis, with enter method and WHO-DAS-II scores as a dependent variable, was performed ( Table 3 ). Only variables that showed statistically significant correlations were entered into the model. The overall regression model for functioning was statistically significant and accounted for 66% of the explained variance (r 2 = 0.66, F = 336.5, df = 7/1216, P < 0.001). There was no evidence of multicollinearity in the model (variance inflation factor of less than 2.5). Residual analysis showed no signs of heteroscedasticity, indicating that the model is appropriate. Depression severity, anxiety severity, age, anxiety state, BMI, trait anxiety, and the presence of an anxiety disorder were, by this order, the significant predictors of functioning.
Discussion
Our aim was to analyze the relation between MDD and anxiety disorder comorbidity and daily function impairment. To our knowledge, our study is the first examining the role of anxiety disorders and anxiety severity on functional impairment in patients with MDD using a specific, comprehensive WHO instrument designed to measure functioning, the WHO-DAS-II. The main findings of our study are partially in accordance with those from previous studies [46] [47] [48] that have examined the comorbidity between anxiety disorder and MDD and its impact on life functioning.
First, in our sample of patients with MDD, about 44% had a comorbid anxiety disorder. Our comorbidity prevalence rates confirm the high rates of comorbidity and are similar (maybe slightly lower) to those from earlier epidemiologic studies. 23, 25, 49, 50 The use of double criteria-DSM-IV anxiety disorders diagnosis and a HARS severity cut-off point of 15 or more-could explain the lower difference.
Second, comparisons between pure and comorbid patients with MDD in our study suggest that anxiety disorder comorbidity may be associated with a less healthy lifestyle, higher depressive severity, higher number of MDE recurrences, and greater disability than when MDD occurs alone. Studies on functioning, comparing pure and comorbid MDD, are inconclusive. In general, most studies agree that patients with comorbid anxiety are more impaired than patients without comorbidity but reported results have been somewhat controversial, showing no differences between patients with and without comorbid anxiety disorder in relation to social dysfunction. 51 Third, when multivariate regression analyses were performed, some of our findings were attenuated. Together, the model accounts for 65% of variance in functioning impairment, with almost all of this variance attributed to MDE severity. Importantly, when both anxiety disorder and MDD are examined simultaneously, anxiety disorder significantly contributes to more impairment in daily activity limitations. The hypothesis that anxiety symptoms would significantly explain variance in overall daily function impairment in patients with MDD was partially supported as anxiety measures explained 5% of the variance, beyond that, it was explained by the other variables in the model. Depression severity alone accounted for 60% of the variance. These findings are similar to those obtained in large epidemiologic studies 10 and should be interpreted while taking into account the assessment measures. As depression and anxiety have many common features, the Hamilton Depression Rating Scale or QIDS includes anxiety symptoms. In our results, there were significant differences in depression severity between groups. Patients with MDD and anxiety disorder have higher scores in the QIDS scale than patients with MDD. In fact, the QIDS Self-Report is a validated self-rated scale to assess severity and the type of depressive symptoms, and also includes anxiety symptoms than may act as a confounder.
Fourth, in our study, poorer functioning was correlated with high trait anxiety scores but not with high state anxiety scores. State anxiety was defined as emotional response while coping with threatening or dangerous situations, and trait anxiety refers to stable individual differences in a tendency to respond with an increase in state anxiety while anticipating threatening situations. 42 Current evidence suggests that high anxiety trait could be an important risk factor for the onset, severity, or outcome of depression. 52, 53 Different neurobiological models discuss the common etiopathogenic or vulnerability factors between personality, anxiety, and depression. 54 There are no works on functioning in comorbid patients with depression and anxiety using STAI-T and STAI-S assessments to compare with our data.
Finally, although comorbidity of major psychiatric disorders with MDD appears to predict a poor clinical outcome in terms of time to recovery, recurrence, and chronicity, 24 our results suggest that this relation could be moderate. Contrary to our hypothesis and some previous findings 12, 20 but according to other studies, 19 we did not observe an influence of previous MDE recurrences on the outcome variable (the WHO-DAS-II score). This result is based on the significant association in the univariate analysis and the nonsignificant association in multivariate analysis. This finding can be explained as variables included in the regression model do not cover all aspects of disability. Also, the way recurrence was collected may be a shortcoming as it was the general practitioner who reported the recurrence and the number of previous MDEs following DSM-IV criteria.
Our study has several limitations as the use of a crosssectional design has implications for generalizability and for establishing causal relations. Our study also includes the use of patient self-reports, without other information from family or friends. Another potential limitation is the absence of an assessment of physical disorders. However, one of the main advantages of the WHO-DAS-II 35 is that it was designed to assess the activity limitations and participation restrictions experienced by an individual irrespective of medical diagnosis. Despite these limitations, our study has several strengths: for example, the sample size is large, compared with prior studies, providing the necessary statistical power to analyze the effect of different variables on functioning. Finally, different measures of anxiety, and not only severity, were considered.
Further research exploring the longitudinal relation of anxiety disorder and MDD with different aspects of inability to function in everyday life situations is essential for a better understanding of the factors that have the greatest impact on the well-being of a patient with MDD.
Conclusions
Comorbid anxiety disorders and anxiety severity appear to be significantly associated with impaired functioning in patients with MDD but explains only a moderate proportion of variance. Monitoring of symptoms, as well as functioning, during the long-term management of MDD could be crucial to achieve functioning remission not affected by residual symptoms of the disease.
